Mobic ads cited for implying superiority
Boehringer Ingelheim newspaper ad for its COX-2 inhibitor Mobic (meloxicam) implies superiority to Merck's Vioxx and Pfizer/Pharmacia's Celebrex, FDA ad division letter says. The ad's "rhetorical question 'Are You Dissatisfied?' implies clinical superiority of Mobic compared with Vioxx or Celebrex in osteoarthritis," the letter says. The ad also makes unsubstantiated claims about international use of the drug and presents risk information in a manner only comprehensible to healthcare professionals, the Oct. 24 letter says...
You may also be interested in...
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
No device-related warning letters were released by the US FDA the week of 26 January.
Karyopharm and GSK should soon learn whether the European Medicines Agency will recommend EU approval for their respective products, selinexor and dostarlimab.